Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: BulbaMan who wrote (2447)	1/3/2001 4:43:06 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

BulbaMan, One caution in looking at the original value of the Cadus investment in Axiom is that it was made as part of a licensing deal and delivery of a machine to Cadus. Thus it isn't clear that Cadus paid the then current fair market value. For that matter, the same may well be true of the Biacore investment. It may well have been disclosed in the Cadus and Biacore filings whether the purchase was intended to be at fair market value or not, as this potentially changes their accounting treatment of the purchase. Is it known what percentage of Axiom Biacore bought compared with Cadus? BTW, if anyone is wondering, the fact that Cadus has written down the Axiom investment to zero is no indication of its true value - it just reflects the portion of the accumulated losses of Axiom that were recorded by Cadus. Peter